跳至主要内容
临床试验/NL-OMON36263
NL-OMON36263已完成4 期

The effect of the addition of dronedarone to, versus increase of, existing conventional rate control medication on ventricular rate during persistent atrial fibrillation (AFRODITE study) - AFRODITE

Sanofi-aventis0 个研究点目标入组 596 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
596

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Paroxysmal AF (according to ACC/AHA/ESC 2006 definition) with HR >80 bpm at rest despite treatment with <=2 rate control agents (i.e. beta blocker and/or calcium antagonist). Patients using digoxin are eligible.
  • Documented AF in the past 24 hours.
  • Treated with the following rate control medication:
  • - beta blocker or
  • - calcium antagonist or
  • - beta blocker plus calcium antagonist or
  • - beta blocker plus digoxin or
  • - calcium antagonist plus digoxin.
  • > 45 years of age.
  • Anticoagulant treatment in line with local guidelines.

排除标准

  • Incapacitated patients.
  • Permanent AF (according to ACC/AHA/ESC 2006 definition).
  • Use of class I or III AADs in the past 3 months.
  • Patients scheduled for cardioversion or pulmonary vein ablation.
  • Unstable NYHA class III and all class IV HF.
  • AV block grade 2 or 3.
  • Known severe renal impairment (serum creatinine >180 µmol/l).
  • Known severe hepatic impairment (AST, ALT >3x ULN).
  • Contra-indication for dronedarone.
  • Participation in a clinical drug study in the 3 months prior to inclusion.
  • Women of childbearing potential, who do not use adequate contraception (in the opinion of the investigator).
  • Lactating women.

研究者

相似试验